Health Care / Chemicals & Pharmaceuticals
Congressional stock trading activity sourced from STOCK Act financial disclosures.
Federal contract context is also available for matched USAspending recipients tied to JNJ.
Total Trades
165
Members
49
Purchases
90
Sales
74
Avg Conflict
16 / 100
High Conflict
4
Total disclosed volume: $2,049,163 - $6,460,000 · Latest trade: Aug 20, 2026
Matched federal spending records can add context when a heavily traded company is also receiving public money. These recipient matches come from USAspending and should be read alongside, not instead of, the underlying trade filings.
Matched recipients
4
Tracked awards
3,846
Matched spending
$43.1M
JOHNSON & JOHNSON matches USAspending recipient JOHNSON & JOHNSON HEALTH CARE SYSTEMS INC., with approximately $39,812,345 in tracked federal spending during the queried window.
JOHNSON & JOHNSON matches USAspending recipient DEPUY SYNTHES SALES, INC., with approximately $2,759,978 in tracked federal spending during the queried window.
30
Members
102
Trades
17 / 100
Avg Score
19
Members
63
Trades
14 / 100
Avg Score
13 Form 4 transactions by 4 insiders in the last 90 days. Buys and sales below count open-market transactions only — Form 4 codes P and S. Grants, option exercises and shares withheld for tax move the share count but are not decisions to trade.
Open-market buys
0
Open-market sales
8
Net shares, all codes
−55,054
Buys per sale
0.00
| Insider | Role | Date | Transaction | Shares | Price | Total Value | Filing |
|---|---|---|---|---|---|---|---|
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17, 2026 |
One card per congressional trade. Where several insiders filed in the same window, the card names the largest and counts the rest.
Lloyd Doggett bought JNJ 2 days before Wengel Kathryn E, EVP, Chief TO and Risk Officer, reported sold on a Form 4.
Lloyd Doggett bought JNJ 2 days before Wengel Kathryn E, EVP, Chief TO and Risk Officer, reported exercised options on a Form 4.
| Date▼ | Member↕ | Type↕ | Amount↕ | Owner | Conflict↕ |
|---|---|---|---|---|---|
| Aug 20, 2026 | John Boozman | sale | $1,001 - $15,000 | joint | 30 / 100 |
| Jul 30, 2026 | Richard McCormick | sale | $1,001 - $15,000 | self | -- |
| Jun 29, 2026 | Thomas H. Kean, Jr. | sale | $1,001 - $15,000 | self | -- |
| Jun 9, 2026 | Lloyd Doggett | purchase | $1,001 - $15,000 | self | 30 / 100 |
| Jun 2, 2026 | Thomas H. Kean, Jr. | sale | $1,001 - $15,000 | self | -- |
| Mar 30, 2026 | Kelly Armstrong | purchase | $1,001 - $15,000 | self | -- |
| Mar 27, 2026 | Kelly Armstrong | purchase | $15,001 - $50,000 | self | -- |
| Mar 26, 2026 | Thomas H. Kean, Jr. | sale | $1,001 - $15,000 | self | 78 / 100 |
| Mar 19, 2026 | John Boozman | sale | $1,001 - $15,000 | self | 30 / 100 |
| Mar 19, 2026 | Richard McCormick | sale | $1,001 - $15,000 | self | 36 / 100 |
| Mar 10, 2026 | Lloyd Doggett | purchase | $1,001 - $15,000 | self | 30 / 100 |
| Jan 23, 2026 | Thomas H. Kean, Jr. | sale | $15,001 - $50,000 | self | 79 / 100 |
| Dec 18, 2025 | Julie Johnson | sale | $1,001 - $15,000 | joint | 36 / 100 |
| Dec 9, 2025 | Lloyd Doggett | purchase | $1,001 - $15,000 | self | 30 / 100 |
| Nov 20, 2025 | Thomas H. Kean, Jr. | sale | $15,001 - $50,000 | self | 84 / 100 |
| Nov 20, 2025 | Thomas H. Kean, Jr. | purchase | Pending | self | 40 / 100 |
| Nov 13, 2025 | Julie Johnson | sale | $1,001 - $15,000 | joint | 31 / 100 |
| Nov 5, 2025 | Richard McCormick | purchase | $1,001 - $15,000 | self | 14 / 100 |
| Oct 31, 2025 | Lisa C. McClain | sale | $1,001 - $15,000 | spouse | 7 / 100 |
| Oct 30, 2025 | Lisa C. McClain | sale | $1,001 - $15,000 | spouse | 7 / 100 |
| Oct 30, 2025 | Lisa C. McClain | purchase | $1,001 - $15,000 | spouse | 7 / 100 |
| Oct 10, 2025 | Jared Moskowitz | sale | $1,001 - $15,000 | child | 2 / 100 |
| Sep 23, 2025 | Val T. Hoyle | sale | $1,001 - $15,000 | spouse | 21 / 100 |
| Aug 19, 2025 | Kelly Morrison | sale | $1,001 - $15,000 | self | 8 / 100 |
| Aug 14, 2025 | Julie Johnson | sale | $1,001 - $15,000 | joint | 1 / 100 |
Other Health Care stocks traded by members of Congress.
JOHNSON & JOHNSON matches USAspending recipient JANSSEN BIOTECH INC, with approximately $464,811 in tracked federal spending during the queried window.
JOHNSON & JOHNSON matches USAspending recipient JANSSEN REFRIGERATION CO, INC, with approximately $50,832 in tracked federal spending during the queried window.
| Open-market sale |
| 15,000 |
| $263.36 |
| $4M |
| SEC Filing |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | Aug 17, 2026 | Option exercise | 15,000 | $115.67 | $1.7M | SEC Filing |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13, 2026 | Open-market sale | 102,315 | $261.00 | $26.7M | SEC Filing |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13, 2026 | Option exercise | 123,291 | $115.67 | $14.3M | SEC Filing |
| Duato Joaquin | CEO and Chairman of the Board | Aug 13, 2026 | Open-market sale | 20,976 | $262.00 | $5.5M | SEC Filing |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 6, 2026 | Open-market sale | 9,344 | $257.75 | $2.4M | SEC Filing |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 6, 2026 | Open-market sale | 6,574 | $255.93 | $1.7M | SEC Filing |
| Forminard Elizabeth | EVP, Chief Legal Officer | Aug 6, 2026 | Option exercise | 9,344 | $131.94 | $1.2M | SEC Filing |
| Duato Joaquin | CEO and Chairman of the Board | Aug 5, 2026 | Open-market sale | 41,957 | $258.06 | $10.8M | SEC Filing |
| Duato Joaquin | CEO and Chairman of the Board | Aug 5, 2026 | Open-market sale | 6,523 | $258.74 | $1.7M | SEC Filing |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20, 2026 | Open-market sale | 23,054 | $251.27 | $5.8M | SEC Filing |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20, 2026 | Option exercise | 11,925 | $131.94 | $1.6M | SEC Filing |
| Broadhurst Vanessa | EVP, Global Corp Affairs | Jul 20, 2026 | Option exercise | 11,129 | $129.51 | $1.4M | SEC Filing |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | Jun 11, 2026 | Open-market sale | 10,000 | $241.15 | $2.4M | SEC Filing |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | Jun 11, 2026 | Option exercise | 10,000 | $115.67 | $1.2M | SEC Filing |
| REED JOHN C | EVP, Innovative Medicine, R&D | May 1, 2026 | Shares withheld for tax | 11,002 | $229.85 | $2.5M | SEC Filing |
| REED JOHN C | EVP, Innovative Medicine, R&D | May 1, 2026 | Option exercise | 25,255 | $0.00 | $0 | SEC Filing |
John Boozman sold JNJ 3 days after Taubert Jennifer L, EVP, WWC. Innovative Medicine, reported exercised options on a Form 4. 1 other insider filed in the same window.
John Boozman sold JNJ 3 days after Taubert Jennifer L, EVP, WWC. Innovative Medicine, reported sold on a Form 4. 1 other insider filed in the same window.
Richard McCormick sold JNJ 6 days before Duato Joaquin, CEO and Chairman of the Board, reported sold on a Form 4. 1 other insider filed in the same window.
Richard McCormick sold JNJ 7 days before Forminard Elizabeth, EVP, Chief Legal Officer, reported exercised options on a Form 4.
ABBOTT LABORATORIES